Single Use Process for Production of AAV Gene Therapy Products
26th January 2022 | 10:00am EST | Lance Marquardt, Associate Director -Upstream Processing Gene Therapy, Hopewell Biologics Manufacturing at PTC Therapeutics |BOOK FREE SEAT FOR THIS WEBINAR
An overview of single use manufacturing for the production of AAV gene therapy products with comparisons to traditional monoclonal antibody production. Specific challenges of scaling up AAV production and considerations to accommodate a range of demands of differing gene therapy products will be discussed. I will review the reasons for starting and the challenges of being the in-house manufacturing facility for a rapidly growing company. The challenges of making non-COVID products in the era of Warp Speed along with future commercial production comparing fully single use with a hybrid facility will be explored.
Presented by Lance Marquardt, Associate Director -Upstream Processing Gene Therapy, Hopewell Biologics Manufacturing at PTC Therapeutics
Lance Marquardt is the Associate Director -Upstream Processing Gene Therapy for Hopewell Biologics Manufacturing at PTC Therapeutics bringing over 20 years of experience in the production of therapeutic proteins for clinical trials. Lance was a key member of the team that revalidated and commissioned a fully single use facility to produce AAV gene therapy product. The facility was previously designed and used manufacture of numerous antibody-based products. He previously led the Upstream Processing group that transitioned from tradition reusable processing to a fully single use production processing at Bristol-Myers Squibb. He received his BS degree in Biotechnology from the University of Wisconsin – River Falls and his MS degree from Kean University.